To the best of our knowledge, this is the first randomized, double-blinded, active-controlled trial on the efficacy of probiotic supplements specifically focusing on BDNF as well as various inflammatory and antioxidant biomarkers in the target population who have already been clinically diagnosed with Alzheimer’s dementia. Here, BDNF is linked to Alzheimer disease.